A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Identifieur interne : 000C55 ( Main/Curation ); précédent : 000C54; suivant : 000C56A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Auteurs : Tian-Tian Yao [République populaire de Chine] ; Jian-Dan Qian [République populaire de Chine] ; Wen-Yan Zhu [République populaire de Chine] ; Yan Wang [République populaire de Chine] ; Gui-Qiang Wang [République populaire de Chine]Source :
- Journal of medical virology [ 1096-9071 ] ; 2020.
Abstract
In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.
DOI: 10.1002/jmv.25729
PubMed: 32104907
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A04
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000A04
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000B84
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000B67
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000B67
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000B67
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :000C57
Links to Exploration step
pubmed:32104907Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.</title>
<author><name sortKey="Yao, Tian Tian" sort="Yao, Tian Tian" uniqKey="Yao T" first="Tian-Tian" last="Yao">Tian-Tian Yao</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Qian, Jian Dan" sort="Qian, Jian Dan" uniqKey="Qian J" first="Jian-Dan" last="Qian">Jian-Dan Qian</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhu, Wen Yan" sort="Zhu, Wen Yan" uniqKey="Zhu W" first="Wen-Yan" last="Zhu">Wen-Yan Zhu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Yan" sort="Wang, Yan" uniqKey="Wang Y" first="Yan" last="Wang">Yan Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Gui Qiang" sort="Wang, Gui Qiang" uniqKey="Wang G" first="Gui-Qiang" last="Wang">Gui-Qiang Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32104907</idno>
<idno type="pmid">32104907</idno>
<idno type="doi">10.1002/jmv.25729</idno>
<idno type="wicri:Area/PubMed/Corpus">000A04</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A04</idno>
<idno type="wicri:Area/PubMed/Curation">000A04</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A04</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B84</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B84</idno>
<idno type="wicri:Area/Ncbi/Merge">000B67</idno>
<idno type="wicri:Area/Ncbi/Curation">000B67</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B67</idno>
<idno type="wicri:Area/Main/Merge">000C57</idno>
<idno type="wicri:Area/Main/Curation">000C55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.</title>
<author><name sortKey="Yao, Tian Tian" sort="Yao, Tian Tian" uniqKey="Yao T" first="Tian-Tian" last="Yao">Tian-Tian Yao</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Qian, Jian Dan" sort="Qian, Jian Dan" uniqKey="Qian J" first="Jian-Dan" last="Qian">Jian-Dan Qian</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhu, Wen Yan" sort="Zhu, Wen Yan" uniqKey="Zhu W" first="Wen-Yan" last="Zhu">Wen-Yan Zhu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Yan" sort="Wang, Yan" uniqKey="Wang Y" first="Yan" last="Wang">Yan Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Gui Qiang" sort="Wang, Gui Qiang" uniqKey="Wang G" first="Gui-Qiang" last="Wang">Gui-Qiang Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of medical virology</title>
<idno type="eISSN">1096-9071</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000C55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV2 |flux= Main |étape= Curation |type= RBID |clé= pubmed:32104907 |texte= A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32104907" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a CovidV2
This area was generated with Dilib version V0.6.33. |